A Common Pigmentation Gene Variant Linked to Faster Parkinson's Progression
MC1R loss-of-function variants, carried by 60%+ of Europeans, are linked to 30–50% faster Parkinson's motor decline.
Summary
Parkinson disease progresses at very different speeds from person to person, and known genes explain only part of that. This study looked at MC1R, a gene best known for skin and hair pigmentation that also helps neurons handle oxidative stress. More than 60% of people of European descent carry at least one weakened version. Among 383 people with sporadic Parkinson disease followed for up to 12 years, carriers lost motor function about 30% faster than noncarriers. In a separate group of 587 clinical trial participants, the gap was about 50%. Carriers of two weakened copies declined fastest. In a small group of people at high risk who did not yet have Parkinson disease, carriers were over four times as likely to develop it. The findings point to a common, easily tested genetic subgroup, which could help with prognosis and clinical trial design.
Detailed Summary
Parkinson disease (PD) follows a highly variable course, and the best-known genetic modifiers, LRRK2 and GBA, explain only a fraction of that variability. Melanocortin 1 receptor (MC1R) is best known for regulating skin and hair pigmentation, but it is also expressed in dopaminergic neurons of the substantia nigra and modulates oxidative stress and cytoprotective pathways. Because 60-70% of people of European descent carry at least one loss-of-function variant, even a modest effect on progression would touch a very large number of patients.
The researchers analyzed the Parkinson Progression Markers Initiative (PPMI). Of 926 participants with PD and genome sequencing, they excluded 66 without dopamine deficiency and 51 carrying pathogenic variants in other PD genes, leaving 809. The primary group was 383 sporadic cases (231 MC1R loss-of-function carriers, 152 noncarriers). The primary outcome was change in off-state MDS-UPDRS Part III over up to 12 years (mean 6.8), analyzed with linear mixed-effects models adjusted for age at onset, sex, race, baseline score, and levodopa dose. Replication used 587 participants from SURE-PD phase 2, SURE-PD3, and STEADY-PD III.
Carriers declined 2.51 points per year versus 1.94 in noncarriers, about 30% faster (β 0.57; 95% CI 0.16-0.98; P = .006). The difference was driven by bradykinesia (1.27 vs 0.94 points/year; P = .001) and orofacial function (P = .03), with no differences in tremor, rigidity, or axial scores. In the replication cohort, carriers declined 4.10 versus 2.73 points per year, about 50% faster (β 1.37; 95% CI 0.28-2.46; P = .01), although follow-up there averaged only 1.35 years.
The association showed a dose-response pattern. Homozygous carriers (n = 20) declined 63% faster (P = .03) and heterozygotes (n = 211) 27% faster (P for trend = .003). Decline rose from noncarriers to low-penetrance to high-penetrance variants (1.94, 2.45, 2.53 points/year; trend P = .01). Results held when restricted to genetically European participants (n = 312; P = .02), adjusted for ancestry principal components, and across age at onset, sex, disease duration, and motor subtype. On-state scores trended the same way but were not significant (P = .30). Cognition, autonomic symptoms, sleepiness, depression, DAT-SPECT, and baseline cerebrospinal fluid biomarkers did not differ.
In 53 PPMI participants with prodromal PD (REM sleep behavior disorder or hyposmia), 23 developed clinical PD: 20 of 34 carriers and 3 of 19 noncarriers. Carriers had a 4.75-fold higher subdistribution hazard (95% CI 1.48-15.27; P = .009). In the pooled sporadic and monogenic cohort, carriers declined 25% faster (P = .008). The effect was nominal in LRRK2 carriers and absent in GBA carriers (2.46 vs 2.56 points/year), though interaction tests were not significant.
The authors suggest MC1R genotyping could help with prognosis and enrich clinical trials for faster progressors. Preclinical work showing that MC1R agonists already used in dermatology are neuroprotective makes this a plausible therapeutic target. Important caveats apply. Secondary analyses were not corrected for multiple comparisons, the prodromal cohort is small with a wide confidence interval, the findings apply mainly to people of European descent, and the study is observational, so causation is not established.
Key Findings
- Sporadic PD (n = 383): MC1R loss-of-function carriers declined 2.51 vs 1.94 off-state MDS-UPDRS III points/year, 30% faster (β 0.57; 95% CI 0.16-0.98; P = .006)
- Independent replication (587 participants from 3 trials): carriers declined 4.10 vs 2.73 points/year, 50% faster (β 1.37; P = .01)
- Dose-dependent effect: homozygotes (n = 20) declined 63% faster (P = .03) vs 27% in heterozygotes (P for trend = .003)
- Faster decline was driven by bradykinesia (1.27 vs 0.94 points/year; P = .001) and orofacial function (P = .03), not tremor, rigidity, or axial signs
- Prodromal PD (n = 53): 20 of 34 carriers vs 3 of 19 noncarriers phenoconverted, subdistribution HR 4.75 (95% CI 1.48-15.27; P = .009)
- Penetrance gradient: 1.94, 2.45, and 2.53 points/year for noncarriers, low-penetrance r carriers, and high-penetrance R carriers (trend P = .01)
- Results held in genetically European participants (n = 312; β 0.50; P = .02), and 60.3% of sporadic PD participants were carriers
Methodology
This longitudinal cohort study used PPMI data (2010-2026; 809 participants with PD, 383 sporadic as the primary group) with up to 12 years of follow-up. The primary outcome was change in off-state MDS-UPDRS III, analyzed with linear mixed-effects models adjusted for age at onset, sex, race, baseline score, and levodopa equivalent daily dose. Replication used pooled data from SURE-PD phase 2, SURE-PD3, and STEADY-PD III (587 participants, mean follow-up 1.35 years). Phenoconversion in 53 prodromal participants was analyzed with a Fine-Gray subdistribution hazards model with competing events. Only the primary analysis was prespecified. Secondary and exploratory analyses had no multiple-comparison adjustment (α = .05).
Study Limitations
Secondary and exploratory analyses were not corrected for multiple comparisons, and the prodromal cohort was small (n = 53) with a wide confidence interval. The replication cohort had short follow-up (mean 1.35 years), used converted UPDRS scores in two trials, and had imputation limits for some variants. Findings apply mainly to people of European descent, and carriers had earlier onset and lower baseline motor scores. Conflict-of-interest disclosures were not included in the supplied text.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: